• A Fumal, P Y Gérardy, and J Schoenen.
• Service Uni- versitaire de Neurologie, Unité de Recherches sur les Céphalées, Hôpital de la Citadelle, Liège, Belgique. Arnaud.Fumal@chu.ulg.ac.be
• Rev Med Liege. 2008 May 1; 63 (5-6): 315-29.

AbstractDespite its high prevalence and individual as well as societal burden, migraine remains underdiagnosed and undertreated. In recent years, the options for the management of migraine patients have greatly expanded. A number of drugs belonging to various pharmacological classes and deliverable by several routes are now available both for the acute and the preventive treatments of migraine. Nevertheless, disability and satisfaction remain low in many subjects because treatments are not accessible, not optimized, not effective or simply not tolerated. There is thus still considerable room for better education and for more efficient therapies. In spite of useful internationally accepted guidelines, anti-migraine treatment has to be individually tailored to each patient taking into account the migraine subtype, the ensuing disability, the patient's previous history and present expectations, and the comorbid disorders. In this article we will summarize the phenotypic presentations of migraine and review recommendations for acute and preventive treatment, highlighting recent advances which are relevant for clinical practice in terms of both diagnosis and management.

8 keywords...

hide…